| Domain | Established finding | Ontology suggestions | Evidence strength / limitations |
|---|---|---|---|
| Disease identity / identifiers | Rare Mendelian developmental disorder originally described as an autosomal-dominant syndrome of uveal colobomata, cleft lip/palate, and intellectual disability; current evidence places it within the YAP1-related ocular coloboma spectrum. OMIM phenotype: **#120433**. Causal gene: **YAP1 (HGNC:16262)**. Do **not** assign MONDO/Orphanet IDs without external confirmation. (pqac-00000001, pqac-00000006) | OMIM: 120433; Gene: YAP1/HGNC:16262; possible disease label string: YAP1-related ocular coloboma syndrome | Strong gene-disease linkage from multiple human families/cases; disease naming and cross-database mapping remain ambiguous. |
| Core ocular phenotype | Congenital uveal/ocular coloboma is the defining feature; reported involvement includes iris, retina/choroid, and optic nerve, often bilateral; microphthalmia/microcornea and nystagmus can co-occur. (pqac-00000003, pqac-00000007, pqac-00000008) | HPO: **Coloboma (HP:0000589)**; **Uveal coloboma (HP:0007707)**; **Iris coloboma (HP:0000612)**; **Chorioretinal coloboma (HP:0000539)**; **Optic nerve coloboma (HP:0000588)**; **Microphthalmia (HP:0000568)**; **Microcornea (HP:0000482)**; **Nystagmus (HP:0000639)** | Strong for ocular phenotype; exact frequency and laterality distribution unavailable due to very small case numbers. |
| Craniofacial / neurodevelopmental syndrome features | Syndromic YAP1-associated disease includes **cleft lip with or without cleft palate**, **learning difficulties/developmental delay/intellectual disability**, and dysmorphic features; historic reports include a stillbirth with anencephaly and cleft lip/palate. (pqac-00000000, pqac-00000001, pqac-00000011) | HPO: **Cleft upper lip (HP:0000204)**; **Cleft palate (HP:0000175)**; **Intellectual disability (HP:0001249)**; **Global developmental delay (HP:0001263)**; **Learning disability (HP:0001328)**; **Anencephaly (HP:0002323)** | Moderate: recurrently cited across later papers, but original 1982 family details were not directly extracted here. |
| Extra-ocular features | Additional reported syndromic manifestations include **sensorineural hearing loss** and **hematuria**; these broaden the phenotype beyond eye and craniofacial findings. (pqac-00000000, pqac-00000006) | HPO: **Sensorineural hearing impairment (HP:0000407)**; **Hematuria (HP:0000790)** | Moderate: based mainly on earlier family reports summarized in later publications. |
| Representative pathogenic / likely pathogenic variants | Reported variants include **NM_001130145.3:c.178dupG p.(Asp60GlyfsTer52)**, a de novo exon-1 frameshift absent from gnomAD; **c.284T>C p.(Phe95Ser)** in a family with isolated coloboma; and **NM_001130145.3:c.1196_1199del** reported as likely pathogenic in routine diagnostics. (pqac-00000002, pqac-00000004, pqac-00000011) | Sequence Ontology: **frameshift_variant**, **missense_variant**; ACMG/AMP concepts: **likely pathogenic**, **de novo** | Strong for existence of these variants; broader allelic series is incompletely captured in available context. |
| Molecular mechanism | Best-supported mechanism is **YAP1 haploinsufficiency / loss of function** affecting **Hippo-YAP signaling**. YAP1 is a transcriptional co-activator regulated by Hippo pathway phosphorylation and TEAD binding; loss disrupts developmental growth-control programs. (pqac-00000007, pqac-00000012, pqac-00000014) | GO: **Hippo signaling (GO:0035329)**; **regulation of cell proliferation (GO:0042127)**; **positive regulation of transcription by RNA polymerase II (GO:0045944)** | Strong mechanistic plausibility from human genetics plus animal/in vitro developmental data; direct human tissue functional assays are limited. |
| Developmental pathophysiology | Evidence supports a role in **optic fissure closure / ocular morphogenesis** and **retinal pigment epithelium (RPE) cell-fate specification**; FAT1-Hippo-YAP dysregulation is a plausible upstream pathway. (pqac-00000012, pqac-00000013) | GO: **eye morphogenesis (GO:0048592)**; **optic fissure closure**; **retinal pigment epithelium development (GO:0061299)**; CL: **retinal pigment epithelial cell (CL:0002586)** | Moderate-to-strong from model systems; exact causal chain for clefting/intellectual disability remains less well defined than for ocular defects. |
| Anatomy / tissues affected | Primary structures: **uvea/iris, retina-choroid, optic nerve, globe size**, and likely embryonic ocular tissues including **RPE, periocular mesenchyme, lens vesicle, neural retina** during development. (pqac-00000006, pqac-00000012) | UBERON: **eye (UBERON:0000970)**, **iris (UBERON:0001769)**, **retina (UBERON:0000966)**, **optic nerve (UBERON:0001138)**, **lens vesicle**, **periocular mesenchyme** | Moderate: anatomy is well supported for eye; non-ocular tissue localization is less disease-specific. |
| Inheritance / penetrance | Inheritance is **autosomal dominant** with **incomplete penetrance** and **variable expressivity**; both familial heterozygous and **de novo** cases are reported. An unaffected mother carrying p.Phe95Ser illustrates reduced penetrance (or possible germline mosaicism). (pqac-00000004, pqac-00000006, pqac-00000007) | HPO inheritance terms: **Autosomal dominant inheritance (HP:0000006)**; **Incomplete penetrance (HP:0003829)**; **Variable expressivity (HP:0003828)** | Strong. Quantitative penetrance estimates are not available. |
| Temporal course | Ocular anomalies are **congenital / early infancy-onset**. Visual function may be impaired from infancy and can worsen in some individuals; one reported patient declined from 20/200 to hand movements over 3 years. (pqac-00000003, pqac-00000004) | HPO: **Congenital onset (HP:0003577)**; **Reduced visual acuity (HP:0007663)** | Limited natural-history data; no formal staging studies. |
| Diagnostics | Most informative test is **molecular sequencing** (WES/WGS or ocular malformation/developmental disorder panels including YAP1), interpreted with phenotype-driven review and careful read-depth assessment. Ophthalmic evaluation may include fundus photography, OCT, and autofluorescence. (pqac-00000006, pqac-00000009, pqac-00000011) | NCIT: **Molecular Genetic Testing**; HPO-driven phenotyping; eye imaging terms; possible panel category: coloboma / microphthalmia panel | Strong for sequencing utility; no disease-specific biomarker, lab assay, or diagnostic criteria guideline identified. |
| Management / real-world care | No disease-modifying therapy is established. Current care is **supportive and multidisciplinary**: ophthalmology/low-vision care, monitoring for cataract and refractive error, cleft team care if present, developmental assessment/support, audiology, and renal/urinary evaluation when indicated by phenotype. (pqac-00000000, pqac-00000006, pqac-00000008) | NCIT: **Supportive Care**, **Ophthalmologic Examination**, **Vision Rehabilitation**, **Cleft Lip Repair**, **Speech Therapy**, **Genetic Counseling** | Indirect but clinically standard; syndrome-specific treatment-outcome studies are lacking. |
| Genetic counseling / prevention | Because AD inheritance with reduced penetrance is documented, **genetic counseling**, family testing/segregation analysis, and consideration of prenatal or preimplantation testing after familial variant identification are reasonable. (pqac-00000004, pqac-00000006, pqac-00000007) | NCIT: **Genetic Counseling**; HPO inheritance terms above | Strong rationale from inheritance pattern; no formal prevention studies exist. |
| Model organisms | **Zebrafish**: yap1 and wwtr1/taz are required for proper **RPE fate specification** in eye development. **Mouse**: heterozygous Yap1 alteration causes Müller glia dysfunction and late-onset cone degeneration; broader Yap1 developmental roles support plausibility. (pqac-00000012, pqac-00000014) | NCBI Taxon: **Danio rerio**, **Mus musculus**; CL: **Müller cell (CL:0002573)** | Moderate: models support ocular developmental biology, but no single model fully recapitulating the full human syndromic triad was identified. |
| Recent developments (2023-2024) | No syndrome-specific 2023-2024 clinical expansion or interventional trial was identified in available searches. Recent work mainly strengthens broader YAP biology and developmental pathway crosstalk rather than this exact syndrome. (pqac-00000012) | GO/Pathway terms above | Important evidence gap; absence of evidence should not be read as disproving future developments. |
| Explicit evidence gaps | No robust data were found for **syndrome prevalence/incidence**, **sex ratio**, **standardized prognosis**, **environmental risk/protective factors**, **gene-environment interactions**, **approved targeted therapy**, or **relevant clinical trials**. (pqac-00000006, pqac-00000011) | Use “not established” rather than assigning ontology IDs | Strong confidence that these are gaps in currently available evidence, not confirmed negatives. |


*Table: This table summarizes the compact evidence base for uveal coloboma-cleft lip/palate-intellectual disability syndrome as part of the YAP1-related ocular coloboma spectrum. It highlights established findings, ontology suggestions, and important limitations for knowledge-base curation.*